Management Recommendation
With an HbA1c of 5.7% (prediabetes range) and lipid values showing triglycerides of 155 mg/dL and LDL-C of 110 mg/dL, initiate intensive lifestyle modification focused on weight loss, dietary changes, and increased physical activity, while addressing the prediabetes and borderline elevated triglycerides as primary targets.
Risk Stratification and Context
Your patient sits at a critical metabolic crossroads:
- HbA1c 5.7% = Prediabetes (diagnostic threshold: 5.7-6.4%)
- Triglycerides 155 mg/dL = Just above the desirable threshold of <150 mg/dL 1
- LDL-C 110 mg/dL = Moderately elevated, but not in severe range (severe = ≥190 mg/dL) 2
The constellation of prediabetes with mildly elevated triglycerides suggests underlying insulin resistance and metabolic syndrome, which drives both the glucose abnormality and the dyslipidemia 3, 4.
Immediate Management Steps
1. Lifestyle Intervention (First-Line, Non-Negotiable)
This is the foundation for both prediabetes and dyslipidemia management:
- Weight loss: Target 5-7% body weight reduction if overweight/obese
- Dietary modifications:
- Reduce saturated fat intake
- Eliminate trans-fats
- Reduce simple carbohydrates and refined sugars (addresses both glucose and triglycerides)
- Increase fiber intake
- Limit alcohol consumption (directly raises triglycerides) 5
- Physical activity: Minimum 150 minutes/week of moderate-intensity exercise
- Address secondary causes: Review medications that may elevate lipids (thiazide diuretics, glucocorticoids, atypical antipsychotics) 2
2. Cardiovascular Risk Assessment
Before initiating pharmacotherapy, you must determine this patient's absolute ASCVD risk:
- Calculate 10-year ASCVD risk score
- Assess for additional risk modifiers:
3. Pharmacotherapy Decision Algorithm
For the lipid management:
The LDL-C of 110 mg/dL does NOT meet criteria for severe hypercholesterolemia (≥190 mg/dL), so the aggressive combination therapy recommendations in 2 do not apply here.
Statin consideration depends on ASCVD risk:
- If 10-year ASCVD risk ≥7.5%: Initiate moderate-intensity statin therapy targeting LDL-C <100 mg/dL 7
- If 10-year ASCVD risk <7.5%: Continue lifestyle modification; reassess in 3-6 months
For the triglycerides (155 mg/dL):
This represents mild hypertriglyceridemia. The primary concern here is ASCVD risk, NOT pancreatitis risk (which becomes relevant at TG >500 mg/dL) 1.
- First-line: Lifestyle modification and statin therapy (if indicated for LDL-C) will also lower triglycerides 1
- Do NOT initiate fibrates or omega-3 fatty acids at this level unless:
- Patient has established ASCVD or diabetes with ≥2 additional risk factors AND
- TG remains 135-499 mg/dL on statin therapy
- Then consider icosapent ethyl 7
For the prediabetes:
- Intensive lifestyle intervention is proven to reduce progression to diabetes by 58%
- Consider metformin if:
- BMI ≥35 kg/m²
- Age <60 years
- History of gestational diabetes
- Progressive hyperglycemia despite lifestyle changes
Critical Pitfalls to Avoid
Don't over-treat the triglycerides: At 155 mg/dL, this is minimally elevated and will likely respond to lifestyle changes and statin therapy if needed. Adding fibrates or prescription omega-3s at this level is premature and not evidence-based 1.
Don't ignore the prediabetes: The HbA1c of 5.7% is the most modifiable risk factor here. Poor glycemic control is directly associated with worsening lipid profiles, particularly elevated TG/HDL-C ratios 3, 4.
Don't start statins reflexively: Unless this patient has additional ASCVD risk factors pushing their 10-year risk ≥7.5%, lifestyle modification should be the initial approach for 3-6 months.
Don't forget secondary causes: Screen for hypothyroidism, obstructive liver disease, nephrotic syndrome, and review all medications 2.
Follow-Up Timeline
- Repeat lipid panel and HbA1c in 3 months after lifestyle intervention
- If HbA1c progresses toward 6.0-6.4% or TG remains >150 mg/dL despite adherence, intensify intervention
- If ASCVD risk is moderate-to-high and LDL-C remains >100 mg/dL, initiate statin therapy
The Bottom Line
The HbA1c of 5.7% is your therapeutic leverage point—addressing insulin resistance through lifestyle modification will simultaneously improve both the glucose metabolism and the lipid profile, particularly the triglycerides 3, 4. Pharmacotherapy should be reserved for patients who fail lifestyle intervention or have elevated baseline ASCVD risk requiring more aggressive LDL-C lowering 6, 7.